A study published in The Lancet Regional Health — Southeast Asia suggests that a higher dose of the COVID-19 drug dexamethasone may have less beneficial effects for patients in India compared to those in Europe. Researchers, including those from Copenhagen University Hospital Rigshospitalet, found that a larger dose (12 mg) did not perform as well as the standard dose (6 mg) in terms of survival rates and patient outcomes after 90 and 180 days. While the evidence is considered weak and could be a chance finding, the study underscores the potential variability in treatment efficacy based on geographic factors and unique challenges in lower-middle-income countries like India.
Dexamethasone Dose Discrepancy: COVID-19 Treatment Variances in India vs. Europe
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2023/11/28083007/Steroid_Dexamethasone-AP-860x574.jpg)